Dr. Lior Shaltiel reports

NUREXONE ESTABLISHING STATE-OF-THE-ART RESEARCH AND DEVELOPMENT FACILITY IN HAIFA, ISRAEL

Nurexone Biologic Inc. has finalized a lease and constructing agreement for nearly 200 square metres of laboratories and office space on the campus of the prestigious Israel Institute of Technology (Technion). The lease period extends until Dec. 31, 2028, with an option to extend for an additional five years.

The Technion's commitment to science research and biotech innovation are reflected in the decision to allocate a new facility on the university's campus to the company. This exclusive location will provide Nurexone with continuing access to top talent, resources and human capital from the university. The new facilities will play a pivotal role in driving the development of the company's revolutionary ExoPTEN and ExoTherapy platform, positioning Nurexone at the forefront of exosome-based therapies advancements.

Dr. Noa Avni, director of research and development at Nurexone, states: "We're pleased to be expanding to a cutting-edge research and development facility on the Technion campus, tailored to our present and future needs for the ExoTherapy platform and ExoPTEN development. In addition, being located at the Technion provides access to multimillion-dollar equipment and advanced facilities at the Technion, streamlining costs for the company. We are deeply grateful to the Technion for their partnership and support."

In the pursuit of constructing a cutting-edge facility that will cater to the needs of the company and its prospective collaboration partners, the company has signed a construction agreement with Biopharmax Group Ltd., a global designer and constructor for leading biotech companies. Construction of the state-of-the-art laboratories and offices is slated for completion within a 12-week period.

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered central nervous system injuries. The company's first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75 per cent of laboratory rats when administered intranasally. ExoPTEN has been granted orphan drug designation by the Food and Drug Administration. The Nurexone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

We seek Safe Harbor.